insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

ASND · Ascendis Pharma A/S - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ASND

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23Q1 '23Q3 '22
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D----------
SG&A----------
Total Operating Expenses----------
D&A----------
Operating Income----------
Interest Expense----------
Income Tax----------
Net Income----------
EPS - Basic----------
EPS - Diluted----------

Balance Sheet

Line itemQ3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23Q1 '23Q3 '22
Cash & Equivalents----------
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets----------
Total Assets----------
Current Liabilities----------
Long-term Debt----------
Total Liabilities----------
Stockholders' Equity----------
Retained Earnings----------

Cash Flow

Line itemQ3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23Q1 '23Q3 '22
Operating Cash Flow----------
Investing Cash Flow----------
Financing Cash Flow----------
CapEx----------
Free Cash Flow----------

Ratios

MetricQ3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23Q1 '23Q3 '22
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets----------
Return on equity----------
Return on invested capital----------
Liquidity
Current ratio----------
Quick ratio----------
Cash ratio----------
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier----------
Liabilities / Assets----------
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)----------
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)----------

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Ascendis Pharma A/S against the 5 most active filers in the same SIC group.